Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance - GBI Research Reports

Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance

Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance - GBI Research Reports
Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance
Published Sep 17, 2011
82 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its latest report, Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance that provides key data, information and analysis of the major trends and developments in post marketing clinical research. The report provides a comprehensive insight into key technological developments, new approaches towards risk mitigation. The report talks about the key regulations, drug classes that require REMS and case studies of drugs for which REMS is required. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Researchs team of industry experts.

Scope

The scope of the report includes -
- Key technological developments, new approaches and strategies to mitigiate drug safety risks
- Preclinical outsourcing market forecast, 2010-2017.
- Analysis of regulation in each of the top geographies in US, Europe and Japan
- Key drivers and barriers that have a significant impact on the industry

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Evaluate the effectiveness of REMS against various classes of drugs that have a poor safety record
- Understand best practices through case studies of REMS application in the industry
- Develop effective strategies to maximize the advantages through the understanding of REMS

  
Source:
Document ID
GBIHC094MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents43
  List of Tables51
  List of Figures61
Post Marketing Clinical Research Introduction71
  GBI Research Report Guidance71
Post Marketing Clinical Research: Overview86
  Introduction81
  Objectives of Post Marketing Clinical Research91
  Establishing Safety through Clinical Trials91
    Pre-Approval Drug Safety91
    Post Marketing Drug Safety101
  Establishing Efficacy through Clinical Trials101
  Limitations of Phase I to Phase III Clinical Trials111
  Pharmaceutical Industry and Drug Safety Challenges121
  Post Marketing Clinical Research: an Unavoidable Necessity for the Pharmaceutical Industry131
    Phase IIIb Studies - Tool to Improve Revenues131
    Post Marketing Clinical Research-Promotes Public Health in Large Populations131
Post Marketing Clinical Research: Objectives and Components1421
  Introduction141
  Objectives of Post Marketing Clinical Research141
    Promoting Public Health141
      Rational Use of Drugs141
      Assessment of Side Effects151
      Long Term Safety and Efficacy161
      Assessing Long Term Pharmacokinetics161
      Designing Public Health Policies171
    Market Development181
      Impact of Post Marketing Surveillance on Life Cycle Management181
      Indication Expansion191
      Formulary Access191
      Product Positioning201
  Components of Post Marketing Clinical Research211
    Risk Evaluation and Mitigation Strategies (REMS)221
      Objectives of REMS221
      Importance of REMS221
      Components of REMS231
    Pharmacoeconomics241
      Introduction241
      Types of Pharmacoeconomic Research251
      Impact of Pharmacoeconomics261
      Health Technology Assessment261
    Pharmacoepidemiology271
      Epidemiology Study Designs272
      Application of Pharmacoepidemiology to Post Marketing Clinical Research291
    Pharmacovigilance291
      Introduction291
      Objectives291
      Importance of Pharmacovigilance301
      Factors Influencing Pharmacovigilance301
      Safety Signal and its Detection313
      Limitations of Pharmacovigilance341
Post Marketing Clinical Research in Special Groups3520
  Post Marketing Studies in Different Population Groups351
    Children351
      Issues of Drug Safety in Children351
      Pediatric Provisions in FDA Amendments Act 2007351
      Pediatric Initiatives in Europe352
      Drug Safety Surveillance Strategies in Children371
    Elderly371
      Issues of Drug Safety in Elderly371
      Impact of Adverse Drug Reactions (ADRs) in the Elderly371
      Pharmacodynamics in the Elderly381
      Pharmacokinetics in the Elderly382
    Pregnancy401
      Drug Labeling and Pregnancy401
      Post Marketing Surveillance Strategies in Pregnant Women412
  Post Marketing Studies in Different Therapy Areas431
    Oncology Therapeutics431
      Accelerated Approval and Oncology Therapeutics431
    Cardiovascular Therapeutics441
    Central Nervous System Therapeutics451
    Gene Therapy451
      Gene Therapy: Basic Process451
      Types of Gene Therapy461
      Post Marketing Surveillance of Gene Therapy461
  Post Marketing Studies in Different Drug Classes471
    Orphan Drugs471
    Vaccines481
      Pharmacovigilance of Vaccines491
    Anti-HIV Drugs501
      Methods of Drug Safety Monitoring of Anti-HIV Drugs501
    Monoclonal Antibodies512
    Blood Products531
      Hemovigilance in Europe531
      Hemovigilance in the US531
      Challenges of Hemovigilance in the US541
Post Marketing Clinical Research - Regulatory Landscape5520
  WHO Approach to Drug Safety551
    WHO Programme for International Drug Monitoring551
    Uppsala Monitoring Centre (UMC)551
      Functions of UMC551
    ICH-GCP and Post Marketing Clinical Research561
  Drug Safety Regulations in the US571
    FDA Amendment Act (FDAAA)571
      Prescription Drug User Fee Amendments, 2007571
      Medical Device User Fee Amendments, 2007571
      Pediatric Research Equity Act, 2007571
      Best Pharmaceuticals for Children Act, 2007571
      Clinical Trial Databases581
      Enhanced Authorities Regarding Post Market Safety of Drugs581
    Implications of FDAAA on Pharmaceutical Industry591
    Role of FDA in Promoting Drug Safety591
    Adverse Event Reporting System602
    Drug Withdrawals from the US Market621
  Drug Safety Regulations in Europe621
    Incidences of Adverse Events in Europe621
    Safety Regulations in Europe621
    European Risk Management Strategy631
    EudraVigilance631
      EudraVigilance Signal Detection Methods631
    Drug Safety Regulations in Europe and the US641
      Similarities of Drug Safety Regulations in the US and the EU641
      Regulations in the EU and the US: Challenges and Advantages641
      Regulations in the EU and the US: New Risk Management Initiatives651
  Drug Safety Regulations in Japan661
    Pharmaceuticals and Medical Devices Agency661
      Application of Data Mining in Safety Surveillance661
      Application of Electronic Records in Safety Surveillance661
    Good Post Marketing Surveillance Practice661
    Good Post Marketing Study Practice671
    Good Vigilance Practice671
    Adverse Drug Reaction Reporting System681
      Adverse Event Reporting by Medical Personnel681
      Adverse Event Reporting by Pharmaceutical Companies691
    Re-Examination and Re-Evaluation System701
  Drug Safety Regulations in Emerging Markets711
    Drug Safety Regulations in China711
      The National Center for Adverse Drug Reaction Monitoring711
      Drug Safety Regulations711
    Drug Safety Regulations in Brazil721
      Pharmacovigilance Unit721
      Functions of Pharmacovigilance Unit721
    Drug Safety Regulations in Russia731
      Drug Safety Regulations731
    Drug Safety Regulations in India731
      National Pharmacovigilance Programme732
Post Marketing Clinical Research and Outsourcing753
  Introduction751
  Advantages of Outsourcing751
  Selection of Outsourcing Partners761
  Phase IV Outsourcing761
  Limitation of Outsourcing771
Post Marketing Clinical Research - Appendix785
  Market Definitions781
  Abbreviations782
  Research Methodology802
    Coverage801
    Secondary Research801
    Primary Research811
    Expert Panel Validation811
  Contact Us811
  Disclaimer811
  Sources821

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Post-Marketing-Clinical-Research-REMS-the-Latest-Reformation-due-to-Post-Marketing-Surveillance-to-Enhance-Patient-Compliance-2115-257>
  
APA:
GBI Research Reports. (2011). Post Marketing Clinical Research - REMS, the Latest Reformation due to Post Marketing Surveillance to Enhance Patient Compliance Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Post-Marketing-Clinical-Research-REMS-the-Latest-Reformation-due-to-Post-Marketing-Surveillance-to-Enhance-Patient-Compliance-2115-257>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.